Overexpression of the PPAR-γ protein in primary Ta/T1 non-muscle-invasive urothelial carcinoma
Peroxisome proliferator-activated receptor-γ (PPAR-γ) is a well-known nuclear receptor that is activated in the nucleus to regulate several transcription factors. Its expression patterns have been examined in various types of cancer. The present study investigated the expression patterns of PPAR-γ i...
Gespeichert in:
| Veröffentlicht in: | Molecular and clinical oncology 2022-02, Vol.16 (2), p.36, Article 36 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 36 |
| container_title | Molecular and clinical oncology |
| container_volume | 16 |
| creator | Tanaka, Shinichi Tokuhara, Yasunori Hosokawa, Sho Ohsaki, Hiroyuki Morinishi, Tatsuya Yamamoto, Tamami Teramoto, Norihiro Hirakawa, Eiichiro |
| description | Peroxisome proliferator-activated receptor-γ (PPAR-γ) is a well-known nuclear receptor that is activated in the nucleus to regulate several transcription factors. Its expression patterns have been examined in various types of cancer. The present study investigated the expression patterns of PPAR-γ in non-muscle-invasive urothelial carcinoma. The expression rates of PPAR-γ, p53 and Ki-67 were compared to determine whether PPAR-γ may be considered as an immunobiomarker for bladder cancer. The intensity and extent of PPAR-γ expression were evaluated in 79 cases of non-muscle-invasive urothelial carcinoma (30 cases of papillary carcinoma low-grade, 30 cases of high-grade and 19 cases of carcinoma
) and 30 non-malignant cases. The nuclear overexpression of PPAR-γ was frequently observed in non-muscle-invasive urothelial carcinoma (63/79 cases) but was rarely detected in non-malignant cases (2/30 cases). The histological proliferation types of non-muscle-invasive urothelial carcinoma revealed that PPAR-γ was more frequently overexpressed in papillary carcinoma (54/60 cases) than in carcinoma
(9/19 cases). Immunohistochemical staining demonstrated that PPAR-γ was more useful as an immunobiomarker than p53 or Ki-67 (diagnostic odds ratios; 55.13, 16.82 and 11.13, respectively). In summary, this study demonstrated that the expression patterns of PPAR-γ were associated with histological proliferation type and that PPAR-γ was expressed in the nuclei of papillary carcinoma cells. These findings suggested that immunohistochemical staining for PPAR-γ may be used to comprehensively detect non-muscle-invasive urothelial carcinoma. |
| doi_str_mv | 10.3892/mco.2021.2469 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8719252</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2621328429</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-1dc0771694d4ff921d3e5d706f8a2939f4b2deb2c1187fd922c38430b3e196483</originalsourceid><addsrcrecordid>eNpVkVtLwzAYhoMobsxdeisBr7vl1ENuhDE8gbAh8zqkaeoibVLTdujv8n_4m0zZHAqB74Pv4c0LDwCXGM1oxsm8Vm5GEMEzwhJ-AsYEMR7xsJ8e9xiNwLRtTY5iSjllPDsHo2EwjOgYiNVOe_3ReB0YZ6ErYbfVcL1ePEffX7DxrtPGwvAab2rpP-FGzjcYWmejum9VpSNjd7I1Ow37AG91ZWQFlfTKWFfLC3BWyqrV08OcgJe7283yIXpa3T8uF0-RYjjuIlwolKY44axgZckJLqiOixQlZSYJp7xkOSl0ThTGWVoWnBBFM0ZRTjXmCcvoBNzsc5s-r3WhtO28rMShtHDSiP8Xa7bi1e1ElmJOYhICrg8B3r33uu3Em-u9DZ0FSQimJGOhyAREe0p517Zel8cfMBKDEhGUiEGJGJQE_upvrSP9K4D-ADyNiO0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2621328429</pqid></control><display><type>article</type><title>Overexpression of the PPAR-γ protein in primary Ta/T1 non-muscle-invasive urothelial carcinoma</title><source>Spandidos Publications Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Tanaka, Shinichi ; Tokuhara, Yasunori ; Hosokawa, Sho ; Ohsaki, Hiroyuki ; Morinishi, Tatsuya ; Yamamoto, Tamami ; Teramoto, Norihiro ; Hirakawa, Eiichiro</creator><creatorcontrib>Tanaka, Shinichi ; Tokuhara, Yasunori ; Hosokawa, Sho ; Ohsaki, Hiroyuki ; Morinishi, Tatsuya ; Yamamoto, Tamami ; Teramoto, Norihiro ; Hirakawa, Eiichiro</creatorcontrib><description>Peroxisome proliferator-activated receptor-γ (PPAR-γ) is a well-known nuclear receptor that is activated in the nucleus to regulate several transcription factors. Its expression patterns have been examined in various types of cancer. The present study investigated the expression patterns of PPAR-γ in non-muscle-invasive urothelial carcinoma. The expression rates of PPAR-γ, p53 and Ki-67 were compared to determine whether PPAR-γ may be considered as an immunobiomarker for bladder cancer. The intensity and extent of PPAR-γ expression were evaluated in 79 cases of non-muscle-invasive urothelial carcinoma (30 cases of papillary carcinoma low-grade, 30 cases of high-grade and 19 cases of carcinoma
) and 30 non-malignant cases. The nuclear overexpression of PPAR-γ was frequently observed in non-muscle-invasive urothelial carcinoma (63/79 cases) but was rarely detected in non-malignant cases (2/30 cases). The histological proliferation types of non-muscle-invasive urothelial carcinoma revealed that PPAR-γ was more frequently overexpressed in papillary carcinoma (54/60 cases) than in carcinoma
(9/19 cases). Immunohistochemical staining demonstrated that PPAR-γ was more useful as an immunobiomarker than p53 or Ki-67 (diagnostic odds ratios; 55.13, 16.82 and 11.13, respectively). In summary, this study demonstrated that the expression patterns of PPAR-γ were associated with histological proliferation type and that PPAR-γ was expressed in the nuclei of papillary carcinoma cells. These findings suggested that immunohistochemical staining for PPAR-γ may be used to comprehensively detect non-muscle-invasive urothelial carcinoma.</description><identifier>ISSN: 2049-9450</identifier><identifier>EISSN: 2049-9469</identifier><identifier>DOI: 10.3892/mco.2021.2469</identifier><identifier>PMID: 34984103</identifier><language>eng</language><publisher>England: Spandidos Publications UK Ltd</publisher><subject>Bladder cancer ; Cancer therapies ; Colorectal cancer ; Gene amplification ; Localization ; Oncology ; Proteins</subject><ispartof>Molecular and clinical oncology, 2022-02, Vol.16 (2), p.36, Article 36</ispartof><rights>Copyright: © Tanaka et al.</rights><rights>Copyright Spandidos Publications UK Ltd. 2022</rights><rights>Copyright: © Tanaka et al. 2020</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-1dc0771694d4ff921d3e5d706f8a2939f4b2deb2c1187fd922c38430b3e196483</citedby><cites>FETCH-LOGICAL-c415t-1dc0771694d4ff921d3e5d706f8a2939f4b2deb2c1187fd922c38430b3e196483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719252/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719252/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34984103$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tanaka, Shinichi</creatorcontrib><creatorcontrib>Tokuhara, Yasunori</creatorcontrib><creatorcontrib>Hosokawa, Sho</creatorcontrib><creatorcontrib>Ohsaki, Hiroyuki</creatorcontrib><creatorcontrib>Morinishi, Tatsuya</creatorcontrib><creatorcontrib>Yamamoto, Tamami</creatorcontrib><creatorcontrib>Teramoto, Norihiro</creatorcontrib><creatorcontrib>Hirakawa, Eiichiro</creatorcontrib><title>Overexpression of the PPAR-γ protein in primary Ta/T1 non-muscle-invasive urothelial carcinoma</title><title>Molecular and clinical oncology</title><addtitle>Mol Clin Oncol</addtitle><description>Peroxisome proliferator-activated receptor-γ (PPAR-γ) is a well-known nuclear receptor that is activated in the nucleus to regulate several transcription factors. Its expression patterns have been examined in various types of cancer. The present study investigated the expression patterns of PPAR-γ in non-muscle-invasive urothelial carcinoma. The expression rates of PPAR-γ, p53 and Ki-67 were compared to determine whether PPAR-γ may be considered as an immunobiomarker for bladder cancer. The intensity and extent of PPAR-γ expression were evaluated in 79 cases of non-muscle-invasive urothelial carcinoma (30 cases of papillary carcinoma low-grade, 30 cases of high-grade and 19 cases of carcinoma
) and 30 non-malignant cases. The nuclear overexpression of PPAR-γ was frequently observed in non-muscle-invasive urothelial carcinoma (63/79 cases) but was rarely detected in non-malignant cases (2/30 cases). The histological proliferation types of non-muscle-invasive urothelial carcinoma revealed that PPAR-γ was more frequently overexpressed in papillary carcinoma (54/60 cases) than in carcinoma
(9/19 cases). Immunohistochemical staining demonstrated that PPAR-γ was more useful as an immunobiomarker than p53 or Ki-67 (diagnostic odds ratios; 55.13, 16.82 and 11.13, respectively). In summary, this study demonstrated that the expression patterns of PPAR-γ were associated with histological proliferation type and that PPAR-γ was expressed in the nuclei of papillary carcinoma cells. These findings suggested that immunohistochemical staining for PPAR-γ may be used to comprehensively detect non-muscle-invasive urothelial carcinoma.</description><subject>Bladder cancer</subject><subject>Cancer therapies</subject><subject>Colorectal cancer</subject><subject>Gene amplification</subject><subject>Localization</subject><subject>Oncology</subject><subject>Proteins</subject><issn>2049-9450</issn><issn>2049-9469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpVkVtLwzAYhoMobsxdeisBr7vl1ENuhDE8gbAh8zqkaeoibVLTdujv8n_4m0zZHAqB74Pv4c0LDwCXGM1oxsm8Vm5GEMEzwhJ-AsYEMR7xsJ8e9xiNwLRtTY5iSjllPDsHo2EwjOgYiNVOe_3ReB0YZ6ErYbfVcL1ePEffX7DxrtPGwvAab2rpP-FGzjcYWmejum9VpSNjd7I1Ow37AG91ZWQFlfTKWFfLC3BWyqrV08OcgJe7283yIXpa3T8uF0-RYjjuIlwolKY44axgZckJLqiOixQlZSYJp7xkOSl0ThTGWVoWnBBFM0ZRTjXmCcvoBNzsc5s-r3WhtO28rMShtHDSiP8Xa7bi1e1ElmJOYhICrg8B3r33uu3Em-u9DZ0FSQimJGOhyAREe0p517Zel8cfMBKDEhGUiEGJGJQE_upvrSP9K4D-ADyNiO0</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Tanaka, Shinichi</creator><creator>Tokuhara, Yasunori</creator><creator>Hosokawa, Sho</creator><creator>Ohsaki, Hiroyuki</creator><creator>Morinishi, Tatsuya</creator><creator>Yamamoto, Tamami</creator><creator>Teramoto, Norihiro</creator><creator>Hirakawa, Eiichiro</creator><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20220201</creationdate><title>Overexpression of the PPAR-γ protein in primary Ta/T1 non-muscle-invasive urothelial carcinoma</title><author>Tanaka, Shinichi ; Tokuhara, Yasunori ; Hosokawa, Sho ; Ohsaki, Hiroyuki ; Morinishi, Tatsuya ; Yamamoto, Tamami ; Teramoto, Norihiro ; Hirakawa, Eiichiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-1dc0771694d4ff921d3e5d706f8a2939f4b2deb2c1187fd922c38430b3e196483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Bladder cancer</topic><topic>Cancer therapies</topic><topic>Colorectal cancer</topic><topic>Gene amplification</topic><topic>Localization</topic><topic>Oncology</topic><topic>Proteins</topic><toplevel>online_resources</toplevel><creatorcontrib>Tanaka, Shinichi</creatorcontrib><creatorcontrib>Tokuhara, Yasunori</creatorcontrib><creatorcontrib>Hosokawa, Sho</creatorcontrib><creatorcontrib>Ohsaki, Hiroyuki</creatorcontrib><creatorcontrib>Morinishi, Tatsuya</creatorcontrib><creatorcontrib>Yamamoto, Tamami</creatorcontrib><creatorcontrib>Teramoto, Norihiro</creatorcontrib><creatorcontrib>Hirakawa, Eiichiro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanaka, Shinichi</au><au>Tokuhara, Yasunori</au><au>Hosokawa, Sho</au><au>Ohsaki, Hiroyuki</au><au>Morinishi, Tatsuya</au><au>Yamamoto, Tamami</au><au>Teramoto, Norihiro</au><au>Hirakawa, Eiichiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overexpression of the PPAR-γ protein in primary Ta/T1 non-muscle-invasive urothelial carcinoma</atitle><jtitle>Molecular and clinical oncology</jtitle><addtitle>Mol Clin Oncol</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>16</volume><issue>2</issue><spage>36</spage><pages>36-</pages><artnum>36</artnum><issn>2049-9450</issn><eissn>2049-9469</eissn><abstract>Peroxisome proliferator-activated receptor-γ (PPAR-γ) is a well-known nuclear receptor that is activated in the nucleus to regulate several transcription factors. Its expression patterns have been examined in various types of cancer. The present study investigated the expression patterns of PPAR-γ in non-muscle-invasive urothelial carcinoma. The expression rates of PPAR-γ, p53 and Ki-67 were compared to determine whether PPAR-γ may be considered as an immunobiomarker for bladder cancer. The intensity and extent of PPAR-γ expression were evaluated in 79 cases of non-muscle-invasive urothelial carcinoma (30 cases of papillary carcinoma low-grade, 30 cases of high-grade and 19 cases of carcinoma
) and 30 non-malignant cases. The nuclear overexpression of PPAR-γ was frequently observed in non-muscle-invasive urothelial carcinoma (63/79 cases) but was rarely detected in non-malignant cases (2/30 cases). The histological proliferation types of non-muscle-invasive urothelial carcinoma revealed that PPAR-γ was more frequently overexpressed in papillary carcinoma (54/60 cases) than in carcinoma
(9/19 cases). Immunohistochemical staining demonstrated that PPAR-γ was more useful as an immunobiomarker than p53 or Ki-67 (diagnostic odds ratios; 55.13, 16.82 and 11.13, respectively). In summary, this study demonstrated that the expression patterns of PPAR-γ were associated with histological proliferation type and that PPAR-γ was expressed in the nuclei of papillary carcinoma cells. These findings suggested that immunohistochemical staining for PPAR-γ may be used to comprehensively detect non-muscle-invasive urothelial carcinoma.</abstract><cop>England</cop><pub>Spandidos Publications UK Ltd</pub><pmid>34984103</pmid><doi>10.3892/mco.2021.2469</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2049-9450 |
| ispartof | Molecular and clinical oncology, 2022-02, Vol.16 (2), p.36, Article 36 |
| issn | 2049-9450 2049-9469 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8719252 |
| source | Spandidos Publications Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Bladder cancer Cancer therapies Colorectal cancer Gene amplification Localization Oncology Proteins |
| title | Overexpression of the PPAR-γ protein in primary Ta/T1 non-muscle-invasive urothelial carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T05%3A51%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overexpression%20of%20the%20PPAR-%CE%B3%20protein%20in%20primary%20Ta/T1%20non-muscle-invasive%20urothelial%20carcinoma&rft.jtitle=Molecular%20and%20clinical%20oncology&rft.au=Tanaka,%20Shinichi&rft.date=2022-02-01&rft.volume=16&rft.issue=2&rft.spage=36&rft.pages=36-&rft.artnum=36&rft.issn=2049-9450&rft.eissn=2049-9469&rft_id=info:doi/10.3892/mco.2021.2469&rft_dat=%3Cproquest_pubme%3E2621328429%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2621328429&rft_id=info:pmid/34984103&rfr_iscdi=true |